La charge de morbidité future estimée du virus de l'hépatite C aux Pays-Bas avec différents paradigmes de traitement
Summary Background & Aims Prevalence of hepatitis C virus (HCV) infection in the Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct-acting antivirals (DAAs) is tolerable and effective but expensive. Our analysis projected the future HCV-related disease burden in the Netherlands by applying different treatment scenarios. Methods Using a modelling approach, the size of […]
French 
English 
Spanish 
Russian 
Arabic